目的 评价抗菌药物管理项目(antimicrobial stewardship program, ASP)对后路腰椎手术患者的临床结局及抗感染治疗费用的影响。方法 回顾性分析2016~2019年于我院骨科行后路腰椎手术并被反馈ASP建议的病例。比较采纳ASP建议与否对患者目标药物治疗天数、住院天数、目标药物费用及抗菌药物总费用、患者30 d感染相关再住院率的影响。结果 2016~2019年,ASP小组共反馈临床建议113例,临床采纳ASP建议54例,拒绝ASP建议59例,采纳率47.79%。采纳ASP建议可以显著减少患者目标药物使用天数(5.0 d vs 6.0 d,P<0.001)及费用(1 559.50元 vs 2 300.27元,P<0.01),同时可以降低患者住院天数(15.5 d vs 17.0 d,P=0.174)及抗菌药物总费用(4 144.96元 vs 5 218.53元,P=0.079)。采纳组与拒绝组患者的30 d感染相关再住院率分别为0 d及1.69%。结论 采纳ASP建议可在不增加感染相关事件的情况下,显著降低后路腰椎手术患者目标药物使用天数及费用,值得在骨科手术的抗菌药物管理中进一步研究。
Abstract
OBJECTIVE To evaluate the effect of antimicrobial stewardship program (ASP) on clinical outcome and expense of anti-bacterial drug in patients undergoing posterior lumbar surgery. METHODS A retrospective research was performed among the patients who underwent posterior lumbar surgery in the orthopedic ward from January 2016 to December 2019 by the intervened ASP database. Duration of therapy with targeted drug, length of hospital stays, 30-day infection-related readmission rate, expense of targeted drug and all antibacterial drugs were compared between interventions accepted and rejected groups. RESULTS Totally 113 interventions were recommended by ASP team and acceptance rate was 47.79%. There were 54 cases in the accepted group and 59 in the rejected group. In comparison with the rejected group, the shorter therapy day of targeted drug (5.0 d vs 6.0 d, P<0.001) and less expense of targeted drugs (1 559.50 yuan vs 2 300.27 yuan, P<0.01) were showed in the accepted group, while shorter length of hospital stays (15.5 d vs 17.0 d, P=0.174) and less expense of total antibacterial drugs (4 144.96 yuan vs 5 218.53 yuan, P=0.079) were also observed in the accepted group. The 30-day infection-related readmission rate was 0 and 1.69% in accepted group and rejected group. CONCLUSION The adoption of recommendation by the ASP team is associated with a reduction in the therapy days and cost of targeted drugs without increasing of postoperative re-infection, which is worthy of further research in orthopedic surgery.
关键词
抗菌药物管理项目 /
后路腰椎手术 /
效果评价 /
合理用药
{{custom_keyword}} /
Key words
antimicrobial stewardship program /
posterior lumbar surgery /
effect evaluation /
rational drug use
{{custom_keyword}} /
中图分类号：
R95
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] DELLIT T H, OWENS R C, MCGOWAN J E J R, et al. Infectious diseases society of america and the society for healthcare epidemiology of america guidelines for developing an institutional program to enhance antimicrobial stewardship[J]. Clin Infect Dis, 2007, 44(2):159-177.
[2] LIU J, LI N, HAO J, et al. Impact of the antibiotic stewardship program on prevention and control of surgical site infection during peri-operative clean surgery[J]. Surg Infect (Larchmt), 2018, 19(3):326-333.
[3] CAMPBELL K A, STEIN S, LOOZE C, et al. Antibiotic stewardship in orthopaedic surgery: principles and practice[J]. J Am Acad Orthop Surg, 2014, 22(12):772-781.
[4] TAVARES M, CARVALHO A C, ALMEIDA J P, et al. Implementation and impact of an audit and feedback antimicrobial stewardship intervention in the orthopaedics department of a tertiary-care hospital: a controlled interrupted time series study[J]. Int J Antimicrob Agents, 2018, 51(6):925-931.
[5] BORDE J P, NUSSBAUM S, HAUSER S, et al. Implementing an intensified antibiotic stewardship programme targeting daptomycin use in orthopaedic surgery: a cost-benefit analysis from the hospital perspective[J]. Infection, 2016, 44(3):301-307.
[6] ZHONG D G, LIU Q Y, MAI X J, et al. Meta-analysis of risk factors of the surgical site infection through lumbar posterior approach[J]. Chin J Tiss Eng Res(中国组织工程研究), 2018,22(15):2427-2436.
[7] YAO R, ZHOU H, CHOMA T J, et al. Surgical site infection in spine surgery: who is at risk[J]. Global Spine J, 2018, 8(4 suppl):5S-30S.
[8] ZHAO J L, FENG L, YIN X J, et al. Study on direct economic losses due to orthopedic surgical site infection in comprehensive hospital[J]. Chin Gen Pract(中国全科医学), 2017, 20(S2):97-98.
[9] ZHOU X C, ZHAO X L, LEI Y, et al. Progress of postoperative infection after lumbar posterior surgery[J]. Chin J Geriatr Orthop Rehabil(中华老年骨科与康复电子杂志), 2019, 5(1):54-57.
[10] WANG L, YANG B, YIN B, et al. Clinical significance of PCT,CRP,ESR,WBC count as predictors in postoperative early infectious complications with fever after posterior lumbar internal fixation[J]. China J Orthop Trauma(中国骨伤), 2015, 28(1):66-70.
[11] ZHANG Z P, GUO Z Q,SUN C G, et al. Microbiological analysis of deep incision infection after posterior thoracic and lumbar internal fixation[J]. J Peking Univ Health Sci(北京大学学报:医学版), 2015,47(2):358-360.
[12] HU F P, GUO Y, ZHU D M, et al. CHINET surveillance of bacterial resistance across tertiary hospitals in 2019 [J]. Chin J Infect Chemother(中国感染与化疗杂志), 2020, 20(3): 233-243.
[13] YE Y. Correlation analysis of fluoroquinolone antibacterial use and resistance rate of common bacteria[J]. Chin J Pharmacovi(中国药物警戒杂志), 2015, 12(7):424-427.
[14] LIU W J, XU Y C, YANG Q W, et al. Surveillance of antimicrobial resistance in Peking Union Medical College Hospital in 2018[J]. Chin J Infect Chemother(中国感染与化疗杂志), 2019, 19(6):639-646.
[15] LOO L W, LIEW Y X, LEE W, et al. Discontinuation of antibiotic therapy within 24 hours of treatment initiation for patients with no clinical evidence of bacterial infection: a 5-year safety and outcome study from Singapore General Hospital Antimicrobial Stewardship Program[J]. Int J Antimicrob Agents, 2019, 53(5):606-611.
[16] RUPALI P, PALANIKUMAR P, SHANTHAMURTHY D, et al. Impact of an antimicrobial stewardship intervention in India: evaluation of post-prescription review and feedback as a method of promoting optimal antimicrobial use in the intensive care units of a tertiary-care hospital[J]. Infect Control Hosp Epidemiol, 2019, 40(5):512-519.
[17] LANGFORD B J, NISENBAUM R, BROWN K A, et al. Antibiotics: easier to start than to stop? Predictors of antimicrobial stewardship recommendation acceptance[J]. Clin Microbiol Infect, 2020, 26(12):1638-1643.
[18] DIK J W, HENDRIX R, POELMAN R, et al. Measuring the impact of antimicrobial stewardship programs[J]. Expert Rev Anti Infect Ther, 2016, 14(6):569-575.
[19] CUNHA C B. The pharmacoeconomic aspects of antibiotic stewardship programs[J]. Med Clin North Am, 2018, 102(5):937-946.
[20] GARCÍA-RODRÍGUEZ J F, BARDÁN-GARCÍA B, PEÑA-RODRÍGUEZ M F, et al. Meropenem antimicrobial stewardship program: clinical, economic, and antibiotic resistance impact[J]. Eur J Clin Microbiol Infect Dis, 2019, 38(1):161-170.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
吴阶平医学基金会临床科研专项基金资助(320.6750.19090-5)
{{custom_fund}}
PDF(1096 KB)
